A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies

This study aimed to determine the maximum-tolerated dose and dose-limiting toxicities of pegylated liposomal doxorubicin (PLD) in combination with temsirolimus (T) in patients with refractory solid tumors. Using a standard “3+3” dose escalation design, 23 patients were enrolled in three dosing cohor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang-Gillam, Andrea, Thakkar, Nilay, Lockhart, A. Craig, Williams, Kerry, Baggstrom, Maria, Naughton, Michael, Suresh, Rama, Ma, Cynthia, Tan, Benjamin, Lee, Wooin, Jiang, Xuntian, Mwandoro, Tibu, Trull, Lauren, Belanger, Stefanie, Creekmore, Allison N., Gao, Feng, Fracasso, Paula M., Picus, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112045/
https://www.ncbi.nlm.nih.gov/pubmed/24916546
http://dx.doi.org/10.1007/s00280-014-2493-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112045/
https://www.ncbi.nlm.nih.gov/pubmed/24916546
http://dx.doi.org/10.1007/s00280-014-2493-x

Ejemplares similares